AI Article Synopsis

  • * A study of 76 children undergoing MRI screening for leukemia diagnosis found that 9.2% had osteonecrotic lesions, primarily in the hips and knees, at the beginning of treatment.
  • * Over a six-month period, the severity and number of osteonecrotic lesions in patients showed unpredictable changes, with some worsening and others improving, but no significant differences were found in patient characteristics between those with and without ON at diagnosis.

Article Abstract

Osteonecrosis (ON) is a common and debilitating side effect of anti-leukemic treatment in children with acute lymphoblastic leukemia (ALL). However, the impact of leukemia itself on ON development remains elusive. We analyzed 76 children enrolled in the ongoing OPAL trial, who had magnetic resonance imaging (MRI) studies at diagnosis. MRI screening revealed 14 osteonecrotic lesions (5 × hips, 9 × knees) of any grade (I-III) in 7 (9.2%) patients. Six months on, the number of ON per patient increased (1 patient), remained constant (2), and decreased (2). The severity increased from grade I to II in two patients, remained constant (1), completely resolved (2), and decreased from grade III to osteoedema (1). No differences between adolescents initially presenting with/without ON were observed concerning age, pubertal stage, body mass index, leukemia characteristics, and clinical presentation. In MRI screening, a remarkable number of adolescents with ALL present with ON at diagnosis. The course of these ON remains highly unpredictable.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1466292DOI Listing

Publication Analysis

Top Keywords

children acute
8
acute lymphoblastic
8
lymphoblastic leukemia
8
mri screening
8
remained constant
8
osteonecrosis children
4
leukemia
4
leukemia initial
4
initial diagnosis
4
diagnosis prior
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!